Dr. Wohl is an associate professor of medicine at the University of North Carolina at Chapel Hill, and co-directs HIV services for the North Carolina Department of Corrections. Dr. Wohl is an investigator in the NIAID-sponsored AIDS Clinical Trials Group (ACTG) and a member of the ACTG Complications of HIV Disease Research Agenda Committee. His research focuses on metabolic and infectious complications of HIV and its therapies, as well as issues related to medication adherence and access to care -- particularly among incarcerated inmates with HIV infection.

After graduating from Boston University in 1986 and receiving an additional Bachelor of Science degree from the Touro College of Biomedical Education in 1988, Dr. Wohl completed his medical education at Robert Wood Johnson Medical School in 1991. He finished residency in internal medicine at Duke University in 1994, after which he began a three-year infectious diseases fellowship at the University of North Carolina-Chapel Hill. He joined the UNC-Chapel Hill faculty shortly thereafter, and hasn't looked back since.

Dr. Wohl's research has appeared in over a half-dozen peer-reviewed journals and several clinical texts. He has taken part in several major HIV conferences, including the 2001 meeting of the International AIDS Society-U.S.A. and the International AIDS Conference in Barcelona, where he co-authored a study on risk behaviors among HIV-positive former prisoners.

Dr. Wohl has won three awards in recent years for his HIV-related research, including the John Carey Young Investigator Award from the National Institutes of Health's AIDS Clinical Trials Unit.

Disclosures

Dr. Wohl has been a consultant for Abbott Laboratories, Tibotec and Merck & Co. He has served on speakers bureaus for Abbott, Gilead, Roche Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim, Tibotec and Merck. In addition, he has received research support from Abbott, Roche and Merck.